Bangor Savings Bank Increases Position in Novo Nordisk A/S (NYSE:NVO)

Bangor Savings Bank lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 1.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,980 shares of the company’s stock after purchasing an additional 243 shares during the period. Bangor Savings Bank’s holdings in Novo Nordisk A/S were worth $1,179,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the company. Bank of New Hampshire increased its stake in Novo Nordisk A/S by 11.8% during the 1st quarter. Bank of New Hampshire now owns 16,143 shares of the company’s stock worth $1,121,000 after buying an additional 1,699 shares in the last quarter. Miracle Mile Advisors LLC acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth approximately $278,000. Sivia Capital Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 9.9% during the 1st quarter. Sivia Capital Partners LLC now owns 8,733 shares of the company’s stock worth $606,000 after purchasing an additional 784 shares during the last quarter. Princeton Global Asset Management LLC boosted its holdings in shares of Novo Nordisk A/S by 52.8% during the 1st quarter. Princeton Global Asset Management LLC now owns 4,250 shares of the company’s stock worth $295,000 after purchasing an additional 1,469 shares during the last quarter. Finally, AAFMAA Wealth Management & Trust LLC boosted its holdings in shares of Novo Nordisk A/S by 23.6% during the 1st quarter. AAFMAA Wealth Management & Trust LLC now owns 21,452 shares of the company’s stock worth $1,490,000 after purchasing an additional 4,095 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Up 2.8%

NYSE:NVO opened at $74.70 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The stock’s fifty day moving average is $65.87 and its two-hundred day moving average is $80.54. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $148.15. The stock has a market capitalization of $335.22 billion, a price-to-earnings ratio of 22.71, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The company had revenue of $11.87 billion for the quarter. Research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Wall Street Analysts Forecast Growth

NVO has been the topic of several recent research reports. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Friday. BNP Paribas began coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an “underperform” rating on the stock. Guggenheim cut Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Finally, Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Two research analysts have rated the stock with a sell rating, six have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $128.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.